Assembly Biosciences, Inc entered into a Common Stock Purchase Agreement and an Investor Rights Agreement with Gilead Sciences, Inc. on October 15, 2023.Pursuant to agreement Gilead made an upfront equity investment of $15 million by purchasing from the Company 13,073,668 shares of the Company?s common stock at a purchase price of $1.16 per share. If the Company completes an equity financing by July 15, 2024 that results in at least $30 million of proceeds to the Company, then, subject to approval by the Company?s stockholders, the Company may require Gilead to purchase additional shares of Common Stock from the Company in an amount that results in Gilead owning 29.9% of the Company?s then-outstanding voting capital stock.